比较半岛逆时针与超脉冲点阵激光治疗萎缩性痤疮瘢痕的疗效与安全性的研究

注册号:

Registration number:

ChiCTR2500106573 

最近更新日期:

Date of Last Refreshed on:

2025-07-25 15:36:13 

注册时间:

Date of Registration:

2025-07-25 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

比较半岛逆时针与超脉冲点阵激光治疗萎缩性痤疮瘢痕的疗效与安全性的研究

Public title:

A study comparing the efficacy and safety of peninsular counter-clockwise and super-pulsed matrix lasers in the treatment of atrophic acne scars

注册题目简写:

English Acronym:

研究课题的正式科学名称:

比较半岛逆时针与超脉冲点阵激光治疗萎缩性痤疮瘢痕的疗效与安全性的研究

Scientific title:

A study comparing the efficacy and safety of peninsular counter-clockwise and super-pulsed matrix lasers in the treatment of atrophic acne scars

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

许家宁 

研究负责人:

徐媛媛 

Applicant:

Xu Jianing 

Study leader:

Xu Yuanyuan  

申请注册联系人电话:

Applicant telephone:

+86 158 4019 7973

研究负责人电话:

Study leader's
telephone:

+86 138 4016 5696

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

15642032930@163.com

研究负责人电子邮件:

Study leader's E-mail:

xyy17101205@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

辽宁省沈阳市和平区南京北街155号

研究负责人通讯地址:

辽宁省沈阳市和平区南京北街155号

Applicant address:

No. 155, Nanjing North Street, Heping District, Shenyang City, Liaoning Province

Study leader's address:

No. 155, Nanjing North Street, Heping District, Shenyang City, Liaoning Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国医科大学附属第一医院

Applicant's institution:

The First Hospital of China Medical University

研究负责人所在单位:

中国医科大学附属第一医院

Affiliation of the Leader:

The First Hospital of China Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

科伦审[2024] 2024-1029-2号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国医科大学附属第一医院伦理科

Name of the ethic committee:

The Ethics Committee of the First Hospital of China Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-11-28 00:00:00

伦理委员会联系人:

王印博

Contact Name of the ethic committee:

Wang Yinbo

伦理委员会联系地址:

辽宁省沈阳市和平区南京北街155号

Contact Address of the ethic committee:

Room 155, Nanjing North Street, Heping District, Shenyang, Liaoning Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 24 8328 2837

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国医科大学附属第一医院

Primary sponsor:

The First Hospital of China Medical University

研究实施负责(组长)单位地址:

辽宁省沈阳市和平区南京北街155号

Primary sponsor's address:

Room 155, Nanjing North Street, Heping District, Shenyang, Liaoning Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

辽宁

市(区县):

Country:

China

Province:

Liaoning

City:

单位(医院):

中国医科大学附属第一医院

具体地址:

辽宁省沈阳市和平区南京北街155号

Institution
hospital:

The First Hospital of China Medical University

Address:

Room 155, Nanjing North Street, Heping District, Shenyang, Liaoning Province

经费或物资来源:

深圳半岛医疗有限公司

Source(s) of funding:

Shenzhen Peninsula Medical Co., Ltd.

研究疾病:

痤疮瘢痕  

Target disease:

Acne scarring

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

比较半岛逆时针与超脉冲点阵激光治疗萎缩性痤疮瘢痕的疗效与安全性  

Objectives of Study:

Comparative efficacy and safety of peninsular counter-clockwise and super-pulsed matrix lasers in the treatment of atrophic acne

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.妊娠期、哺乳期妇女; 2.严重心、肝、肾功能不全者,或患有自身免疫性疾病者; 3.安装心脏起搏器或体内除颤器者; 4.3个月内曾行激光、射频、化学剥脱、肉毒素注射等患者; 5.1个月内前使用过光敏性药物、维A酸类药物; 6.1个月内服用糖皮质激素或其他免疫抑制剂、抗凝药; 7.1年内接受磨削治疗者、填充剂注射史; 8.感染病史例如人免疫缺陷病毒感染者; 9.不能坚持治疗者; 10.治疗区域内皮肤有破损性、开放性伤口、化脓性伤口及活动期炎性疱疹等皮肤疾病; 11.患有凝血功能障碍或其他系统性疾病者; 12.治疗区存在恶性肿瘤或不明性质的皮肤肿瘤者; 13.正在接受化疗/放疗者。

Exclusion criteria:

1. Pregnant and lactating women; 2. Severe heart, liver, and kidney insufficiency, or those with autoimmune diseases; 3. Those who are equipped with a pacemaker or internal defibrillator; 4. Patients who have undergone laser, radiofrequency, chemical peeling, botulinum toxin injection, etc. within 3 months; 5. Use of photosensitizing drugs and tretinoin drugs within 1 month; 6. Taking glucocorticoids or other immunosuppressants and anticoagulants within 1 month; 7. History of grinding treatment and filler injection within 1 year; 8. History of infection, such as human immunodeficiency virus infection; 9. Those who cannot adhere to treatment; 10. Skin diseases such as broken, open wounds, purulent wounds, and active inflammatory herpes in the treatment area; 11. Those who suffer from coagulation dysfunction or other systemic diseases; 12. Those who have malignant tumors or skin tumors of unknown nature in the treatment area; 13. Subjects who are receiving chemotherapy/radiotherapy.

研究实施时间:

Study execute time:

From 2025-01-06 00:00:00 To 2025-05-13 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-01-06 00:00:00 To 2025-05-13 00:00:00

干预措施:

Interventions:

组别:

A组

样本量:

20

Group:

A Group

Sample size:

干预措施:

点阵激光治疗

干预措施代码:

Intervention:

Fractional carbon dioxide laser treatment method

Intervention code:

组别:

B组

样本量:

20

Group:

B Group

Sample size:

干预措施:

微针射频治疗

干预措施代码:

Intervention:

Microneedle radiofrequency treatment method

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

辽宁 

市(区县):

 

Country:

China

Province:

Liaoning

City:

单位(医院):

中国医科大学附属第一医院 

单位级别:

三甲 

Institution
hospital:

The First Hospital of China Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

痤疮瘢痕权重评分

指标类型:

主要指标

Outcome:

ECCA (échelle d'evaluation clinique des cicatrices d' acné)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者满意度自评

指标类型:

主要指标

Outcome:

Self-assessment of patient satisfaction

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

黑素指数

指标类型:

次要指标

Outcome:

Melanin index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

棕色斑

指标类型:

次要指标

Outcome:

Brown spot

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

水分含量

指标类型:

次要指标

Outcome:

Moisture content

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

油脂含量

指标类型:

次要指标

Outcome:

Oil content

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

红斑指数

指标类型:

次要指标

Outcome:

Erythema index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

紫外线色斑

指标类型:

次要指标

Outcome:

Ultraviolet spots

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

纹理

指标类型:

次要指标

Outcome:

Texture

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

皱纹

指标类型:

次要指标

Outcome:

Wrinkle

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

毛孔

指标类型:

次要指标

Outcome:

Pore

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

卟啉

指标类型:

主要指标

Outcome:

Porphyrin

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良反应

指标类型:

副作用指标

Outcome:

Adverse reactions

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数字表法

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number table method

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

国家生物信息中心 https://ngdc.cncb.ac.cn/gsub/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

China National center for Bioinformation https://ngdc.cncb.ac.cn/gsub/

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用病历记录表进行数据统计,使用 SPSS软件处理数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data statistics were performed using the medical record form, and data were processed using SPSS software.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-07-25 15:36:00